Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
ConditionMild Stroke
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorSecond Affiliated Hospital of Soochow University
About this trial
This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.
Eligibility criteria
Qualifiers
Age: 18-80 years old.
Acute mild non-cardioembolic stroke.
NIHSS score ≤5.
Time from onset to randomization of ≤48 hours; if the time of onset is unknown, time from the last known time of being well to randomization of ≤48 hours.
Disqualifiers
Received or planned to receive intravenous thrombolysis or bridging therapy (with subsequent endovascular treatment)
Intracranial hemorrhage confirmed by imaging.
Pre-stroke modified Rankin Scale (mRS) score ≥2.
Any confirmed cardioembolic source, including chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, infective endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction <30%.
Trial design
Treatments tested in this trial
- Tirofiban+Oral Dual Antiplatelet Therapy
- Oral Dual Antiplatelet Therapy
Treatment groups
580 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov